Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for COGT.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 14.28M
March 31, 2026 -36.46M
December 31, 2025 -322.77M
September 30, 2025 -155.05M
June 30, 2025 8.91M
March 31, 2025 69.38M
December 31, 2024 61.67M
September 30, 2024 60.19M
June 30, 2024 -84.62M
March 31, 2024 1.044M
December 31, 2023 10.49M
September 30, 2023 -90.54M
June 30, 2023 -77.66M
March 31, 2023 59.88M
December 31, 2022 28.41M
September 30, 2022 -151.54M
June 30, 2022 -1.144M
March 31, 2022 -0.441M
Date Value
December 31, 2021 -0.433M
September 30, 2021 -1.163M
June 30, 2021 -0.123M
March 31, 2021 0.00
December 31, 2020 0.00
September 30, 2020 8.42M
June 30, 2020 0.00
March 31, 2020 0.00
December 31, 2019 -0.013M
September 30, 2019 0.226M
June 30, 2019 7.996M
March 31, 2019 14.95M
December 31, 2018 15.00M
September 30, 2018 9.914M
June 30, 2018 -41.37M
March 31, 2018 5.925M
December 31, 2017 4.90M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Apogee Therapeutics, Inc. -381.86M
Erasca, Inc. 19.49M
Moderna, Inc. 329.00M
Arrowhead Pharmaceuticals, Inc. 43.68M
Oncolytics Biotech, Inc. 0.00